RxDoctor Payments Data

Jeffrey Prater, NP

Psychiatric/Mental Health · Elizabethtown, KYNPI 1659401461

Payments from drug & device makers

$3,011in general payments, 2019–2025

Across 195 payments — averaging $15.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$769
  • AbbVie$559
  • Alkermes, Inc.$284
  • Otsuka America Pharmaceutical, Inc.$265
  • Lundbeck LLC$259
  • Vanda Pharmaceuticals Inc.$216
  • plus $659 from 12 others

What the payments were for

  • Food & beverage$2,95098%
  • Education$612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,011 in reported general payments places this provider in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$7,513
Medicare patients
34
Services billed
86

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl55$96,260
RexultiBrexpiprazole21$32,853
TrintellixVortioxetine Hydrobromide12$12,943
Aripiprazole72$8,077
Quetiapine Fumarate208$5,589
Olanzapine50$2,284
Bupropion XlBupropion Hcl90$2,201
Ziprasidone Hcl14$1,930
Divalproex Sodium18$1,853
Lamotrigine181$1,825
Clonazepam266$1,761
Divalproex Sodium ErDivalproex Sodium30$1,756
Mirtazapine99$1,755
Methylphenidate Hcl38$1,627
Hydroxyzine Hcl73$1,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$559$96,26055 claims
Otsuka America Pharmaceutical, Inc.Rexulti$265$32,85321 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$63$12,94312 claims
Lilly USA, LLCOlanzapine$30$2,28450 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Elizabethtown

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →